Subscribe to Entrepreneur for $5

Dynavax (DVAX) Gains on Clover's COVID-19 Vaccine Study Data

Dynavax (DVAX) stock gains as partner Clover announces strong efficacy of its COVID-19 vaccine candidate against the Delta variant in pivotal study da...

This story originally appeared on Zacks

Shares of Dynavax Technologies Corporation DVAX jumped 26.5% on Sep 22 after its Taiwan-based partner, Clover Biopharmaceuticals announced positive data from a pivotal study evaluating the latter’s COVID-19 vaccine candidate.

- Zacks

Clover was evaluating its vaccine candidate, SCB-2019, adjuvanted with Dynavax's CpG 1018 adjuvant in a phase II/III study — SPECTRA. Data from the study demonstrated that immunization with the candidate led to overall efficacy of 100% against severe COVID-19 and hospitalization, and 84% against moderate-to-severe COVID-19 caused by currently leading strains of coronavirus, including Delta, Gamma, and Mu variants. The vaccine candidate achieved an overall efficacy of 67% against COVID-19 infection of any severity caused by any strain in the study.

The SPECTRA study evaluated SCB-2019 adjuvanted with CpG 1018 adjuvant against different variants of the original SAR-CoV-2 virus. Data from the study demonstrated an overall efficacy of the vaccine candidate of 79%, 92%, and 59% against the Delta variant, the Gamma variant, and the Mu variant, respectively. The study data also demonstrated that the vaccine reduced the risk of breakthrough infections.

Shares of Dynavax have surged 322.3% so far this year compared with the industry’s growth of 0.6%.

Zacks Investment Research

Image Source: Zacks Investment Research

Although the leading COVID-19 vaccine makers — Pfizer PFE, Moderna MRNA, and J&J JNJ — have already supplied millions of doses to the world, coronavirus vaccines under development also hold strong potential as there is requirement of several billions of doses across the globe. Several companies developing vaccines may benefit from the current COVID-19 situation. Clover’s strong efficacy against the prevalent Delta variant and breakthrough infections make it one of the top contenders to gain significantly. Per Clover, the Delta variant is the most prevalent strain of the coronavirus currently across the globe with 90% of infection cases caused due to the variant.

Moreover, Clover’s agreement with the Coalition for Epidemic Preparedness Innovations (“CEPI”) will guarantee expedited distribution of the vaccine, once approved/authorized.

Dynavax’s shares also gained last month following the rollout of its Taiwan-based partner Medigen Vaccine Biologics’ COVID-19 vaccine — MVC-COV1901 — in the East Asian country.

Net product revenues from CpG 1018 adjuvant during the second quarter of 2021 were $39.0 million. We note that successful distribution/commercialization of Clover’s and Medigen’s COVID-19 vaccines following an authorization/approval will also be beneficial for Dynavax as it will generate additional revenues under its collaboration with Clover.

Zacks Rank

Dynavax currently has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

More Stock News: This Is Bigger than the iPhone!

It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 77 billion devices by 2025, creating a $1.3 trillion market.

Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 4 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2022.

Click here for the 4 trades >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report


Dynavax Technologies Corporation (DVAX): Free Stock Analysis Report


Johnson & Johnson (JNJ): Free Stock Analysis Report


Pfizer Inc. (PFE): Free Stock Analysis Report


Moderna, Inc. (MRNA): Free Stock Analysis Report


To read this article on click here.


Zacks Investment Research